Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy-Reference-Cited by-同舟云学术

Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy

Published:2018-12 Issue:6 Volume:79 Page:1081-1088
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Siegel Jacob,Totonchy Mariam,Damsky William,Berk-Krauss Juliana,Castiglione Frank,Sznol Mario,Petrylak Daniel P.,Fischbach Neal,Goldberg Sarah B.,Decker Roy H.,Stamatouli Angeliki M.,Hafez Navid,Glusac Earl J.,Tomayko Mary M.,Leventhal Jonathan S.

Funder

Merck

AstraZeneca

Bayer

Publisher

Elsevier BV

Subject

Dermatology

Reference14 articles.

1. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy;Shi;JAMA Dermatol,2016

2. PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases;Wakade;Melanoma Res,2016

3. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy;Curry;J Cutan Pathol,2017